Kuro Games announced the events and banners for Wuthering Waves version 2.3 Phase 2 (Image via Kuro Games) Kuro Games announced all the events and banners coming with Wuthering Waves 2.3 second phase.

For those wondering, this article takes a look at the upcoming Honkai Star Rail 3.3 first phase events. As usual, the developers, HoYoverse, will release a new Trailblaze Mission for all players.

Phase 2 of the Wuthering Waves 2.3 update officially kicked off on May 22, 2025, and it features several Resonators. Ciaccona is the newest entry to the playable roster – she hails from the Aero ...

Mumbai: Two major infrastructure projects Phase 2 of the Metro-3 corridor and the final phase of the Samruddhi Expressway most likely to be opened to the public on May 1st According to sources ...

In a big leap for Mumbai’s public transport, Metro Line 3's second phase—connecting Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli—officially began operations on Saturday ...

This study is the first randomized, double-blind, controlled Phase 3 clinical study evaluating biologics switching in psoriasis patients with prior inadequate response to anti-IL-17 antibody.

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed ...

The regulatory filing states that enrollment in the global Phase 3 HAELO study of NTLA-2002 for hereditary angioedema is on track. The company expects to complete enrollment in the third ...

The Massachusetts biotech reported May 19 that AD109 met the primary endpoint of a phase 3 trial, reducing sleep apnea severity by a statistically significant 55.6% compared to baseline.

The THRIVE phase 3 clinical trial in active TED evaluated 5 infusions of veli or placebo every three weeks with primary topline analysis at week 15 and then followed patients through week 52.

"The positive results from our Phase 3 SynAIRgy trial bring us closer to realizing our vision of offering a simple, safe, and effective oral drug — one that is grounded in science, driven by ...